Drugs
A team of five industry leaders, including Genencor International, Eastman Chemical Company, Electrosynthesis Company Inc., MicroGenomics Inc., and Argonne National Laboratory, has achieved a significant milestone in developing new methods to manufacture chemicals from renewable resources. The first target chemical, ascorbic acid (vitamin C), has a worldwide market of approximately
Drugs
Selective Genetics, Inc. has acquired the exclusive license to U.S. Patent Number 5,763,416, "Gene transfer into bone cells and tissues," which was issued to the University of Michigan on June 9, 1998. The patent covers the company's Gene Activated Matrix (GAM) technology for
Drugs
Schering-Plough, a research-based pharmaceutical company, and Immune Response, a biopharmaceutical company, have entered a research collaboration and option agreement to develop gene therapy products for the treatment of hepatitis B and C, and other diseases. The collaboration combines Immune Response's proprietary GeneDrug gene delivery technology with Schering-Plough'
Drugs
Researchers at Ventana Genetics have developed a novel approach to rapidly identifying key molecules and genes involved in physiological processes, as published in the Proceedings of the National Academy of Sciences (PNAS). The company's method, which combines functional screening with advanced genetics and assay technologies, can be applied
Drugs
Abgenix, a biopharmaceutical company, has announced the expansion of its research license and option agreement with Genentech, Inc. The new agreement allows Genentech to use Abgenix's proprietary XenoMouse technology to generate fully human antibodies to a second antigen target in the area of cardiovascular research. In return, Abgenix
Drugs
Axys Pharmaceuticals and Roche Bioscience announced a collaboration to evaluate the function of genes provided by Roche Bioscience as potential targets for therapies in pain and other conditions involving peripheral nervous system disorders. The alliance will utilize Axys' functional genomic technologies and the model animal system Caenorhabditis elegans (C.
Drugs
Targeted Genetics Corporation has made significant strides in developing a gene therapy for cystic fibrosis (CF), with the company's proprietary vector, tgAAV-CFTR, demonstrating safe and effective gene transfer in a Phase I trial. The study, conducted at Stanford University's School of Medicine, involved 10 patients with
Drugs
Genelabs Technologies, a diversified international biopharmaceutical and diagnostics company, has announced the completion of the first phase of financing for its Taiwanese joint venture, Genelabs Biotechnology Limited (GBL). The initiative, valued at NT$153 million, marks a significant milestone in the collaboration between Genelabs and the Taiwanese government, aiming to
Drugs
Researchers from the Medical College of Wisconsin, the Good Samaritan Hospital Heart Institute, the University of Southern California, and the Hatter Institute have found that the preventive use of MPL-C immunomodulator significantly reduces cardiac infarct size by more than 50% compared to controls. This discovery was made through preclinical data
Drugs
The US Food and Drug Administration (FDA) has announced the elimination of special restrictions on biotechnology drugs, a move that is expected to save the industry hundreds of millions of dollars and accelerate the development of new treatments. The change in policy comes as the FDA has approved 32 biotech
Drugs
Cambridge NeuroScience, Inc. reported a net loss of $2.8 million for the third quarter ended September 30, 1995, a decrease of 38% from the comparable period in 1994. However, the company made significant progress in the clinical development of CERESTAT(R), a treatment for stroke and traumatic brain injury.
Drugs
Immunex Corporation, a biopharmaceutical company, received an unexpected proposal from American Home Products Corporation to acquire all outstanding shares of Immunex's common stock not held by AHP at $14.50 per share in cash. This move comes after AHP's indirect ownership of 54.6 percent of
